Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aurora Cannabis Inc T.ACB

Alternate Symbol(s):  T.ACB.WS.U | ACB

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution, and sale of cannabis related products in Canada and internationally. The Company’s segments include Canadian Cannabis, European Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol and CraftPlant. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia, and Odense, Denmark. The Company is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets.


TSX:ACB - Post by User

Bullboard Posts
Post by rehsifylfon Apr 11, 2018 3:54pm
120 Views
Post# 27868872

Relative Valuation

Relative ValuationThe problem with looking at stock prices and comparing them to each other over the the prior twelve months, or even the prior 6 months, is that the companies have changed/diluted/acquired significantly for some (APH and ACB),and less so for others (WEED) over the past 6 months.

For ACB, APH, and WEED here is what the last 6 months look like:

WEED

Oct 11, 17 - 185.79 Million Shares @ $13.59 = Market Cap $2.52B
Jan 11, 18 - 192.43 Million Shares @ $37.56 = Market Cap $7.22B (286% higher than Oct)
Apr 11, 18 - 198.35 Million Shares @ $28.00 = Market Cap $ 5.5 B (218% higher than Oct)

Increase in # of Shares ~ 7%

ACB

Oct 11, 17 - 396.91 Million Shares @ $3 = Market Cap $1.2 B
Jan 11, 18 - 489.92 Million Shares @ $13.24 = Market Cap $6 B (500% higher than Oct)
Apr 11, 18 - 563 Million Shares @ $8 = Market Cap $4.5 B (375% higher than Oct)

Increase in # of Shares ~ 41%

APH

Oct 11, 17 - 138.9 Million Shares @ $7.84 = Market Cap $1.09 B
Jan 11, 18 - 160 Million Shares @ $20.55 = Market Cap $3.29 B (300% higher than Oct)
Apr 11, 18 - 174.3 Million Shares @ $10.13 = Market Cap $1.76 B (161 % higher than Oct)

Based on this - ACB has had the most growth in the past 6 months, even at current prices.  APH has grown the least in value (by far).  The question is, how much impact (positive or negative) will the moves these companies have made in the past 6 months have on future revenue and earnings.

Increase in # of Shares ~ 25.4%
Bullboard Posts